Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis

Indian Journal of Pharmacology

Volumn 45, Issue 1, 2013, Pages 54-60

  Hiremath, Sharanabasayyaswamy B ^a   Srinivas, L D ^b  

^a SDM COLLEGE OF MEDICAL SCIENCES AND HOSPITAL   (India)

^b J J M MEDICAL COLLEGE   (India)

Author keywords

albumin; Hepatorenal syndrome; N Acetylcysteine; terlipressin

Indexed keywords

TERLIPRESSIN;

ARTICLE; HEPATORENAL SYNDROME; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL; TREATMENT RESPONSE;

ALBUMIN; HEPATORENAL SYNDROME; N-ACETYLCYSTEINE; TERLIPRESSIN;

DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATORENAL SYNDROME; HUMANS; LYPRESSIN; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84874859026     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.106436     Document Type: Article

References (35)

1. Fernandez J, Arroyo V. Novel Defi nition of Hepatorenal Syndrome: Clinical Consequences. Front Gastrointest Res 2011;28:122-9.
2. Tandon P, Bain VG, Tsuyuki RT, Klarenbach S. Systematic review: Renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther 2007;25:1017-28.
3. Hani MW, Martin LM, Nasimul A, Thomas AG. Hepatorenal Syndrome: Pathophysiology and Management. Clin J Am Soc Nephrol 2006;1:1066-79.
4. Gluud LL, Christensen K, Christensen E, Krag A. Systematic Review of Randomized Trials on Vasoconstrictor Drugs for Hepatorenal Syndrome. Hepatology 2010;51:576-84.
5. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. J Hepatol 2011;55:315-21.
6. Nancy GB, Robert AP. Meta-analysis: Neither quick nor easy. BMC Med Res Methodol 2002;2:10.
7. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A Randomized, Prospective, Double-Blind, Placebo Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology 2008;134:1360-8.
8. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Benefi cial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebocontrolled clinical trial. J Gastroenterol Hepatol 2003 ;18:152-6.
9. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome. Dig Dis Sci 2008;53:830-5
10. Martín-Llahí M, Pepin M, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and Albumin vs Albumin in patients with cirrhosis and Hepatorenal Syndrome: A Randomized Study. Gastroenterology 2008;134:1352-9
11. Sharma P, Kumar A, Shrama BC, Sarin SK. An Open Label, Pilot, randomized Controlled Trial of Noradrenaline versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response. Am J Gastroenterol 2008;3:1689-97.
12. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Torrani M, Cerenzia S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective,randomized, unblinded, pilot study. J Hepatol 2007;47:499-505.
13. Singh V, Ghosh S, Chawla Y, Singh B, Sharma N, Bhalla A, et al. Noradrenaline Versus Terlipressin in the Treatment of Hepatorenal Syndrome. Gastroenterology 2011;140 (Suppl 1):S-958.
14. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Benefi cial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
15. Srivastava S, Madan K, Prakash S, Sreenivas V, Khanal SP, Acharya SK. A Randomized Controlled Trial of Terlipressin and Albumin Versus Albumin, Low Dose Dopamine and Frusemide in Hepatorenal Syndrome. J Clin Exp Hepatol 2011;1(Suppl 1):23-4.
16. Angeli, P,Fasolato S, Cavallin M, Trotta E, Maresio G, Callegaro A, et al. Terlipressin given as continuous intravenous infusion versus terlipressin given as intravenous boluses in the treatment of type 1 hepatorenalsyndrome (hrs) in patients with cirrhosis. J Hepatol 2009;50(Suppl 1):S73.
17. Romero SM, Pascasio JM, Sousa JM, Cayuela A, Ferrer MT, Gómez-Navarro E, et al. Terlipressin and albumin in cirrhotic patients with hepatorenal syndrome type-1 with and without active infection. J Hepatol 2008;48 (Suppl 2):S123.
18. Yang YZ, Dan ZL, Liu NZ, Liu M. Effi cacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. J Intern Intensive Med 2001;7:123-5.
19. Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, et al. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenterology 2003;50 :ccciii-cccv.
20. Angeli P. Terlipressin for Hepatorenal syndrome: Novel strategies and future perspectives. Front Gastrointest Res 2011;28:189-97.
21. Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, et al. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann Hepatol 2009;8:207-11.
22. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and Octreotide. Hepatology 1999;29: 1690-7.
23. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-5.
24. Gressner OA, Siluschek M, Lahme B, Gressner AM. Endothelin-receptor antagonist/Nacetylcysteine combination in type 1 hepatorenal syndrome. J Hepatol 2009;50:1051-6.
25. Wong F, Moore K, Dingemanse J, Jalan R. Lack of Renal Improvement with Nonselective Endothelin Antagonism with Tezosentan in Type 2 Hepatorenal Syndrome. Hepatology 2008;47:160-8.
26. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk of nephropathy: Decrease in oxidant stress mediated tubular injury. Nephrol Dial Transplant 2004;19:1803-7.
27. Alcaraz A, Iyu D, Atucha NM, Garća-Estan J, Ortiz MC. Vitamin E supplementation reverses renal altered vascular reactivity in chronic bile duct-ligated rats. Am J Physiol Regul Integr Comp Physiol 2007;292:R1486-93.
28. Ortiz MC, Manriquez CM, Nath KA, Lager DJ, Romero JC, Juncos LA. Vitamin E prevents renal dysfunction induced by experimental chronic bile duct ligation. Kidney Int 2003;64:950-61.
29. Bomzon A, Ljubuncie P. Oxidative stress and vascular smooth muscle cell function in liver disease. Pharmacol Ther 2001;89:295-308.
30. Beate A, Julia Z, Karl AB, Jörg H, Tilman S, Michael S. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: A retrospective analysis. Eur J Gastroenterol Hepatol 2009;21:1428-32.
31. Davis NA, Garcia R, Proven A, Jalan R. Albumin: Not just a plasma expander. In: Gerbes AL, editor. Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment. Vol. 28. Basel: Karger; 2011. p. 40-51.
32. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
33. Moreau R, Durand F, Poynard C, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in Patients with Cirrhosis and Type 1 Hepatorenal Syndrome: A Retrospective Multicenter Study. Gastroenterology 2002;122:923-30.
34. Sen S, Mookerjee RP, Jalan R. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: A case for combined use in hepatorenal syndrome Gastroenterology 2002;123:2160-1.
35. Martinez MO, Harlan S, Renuga V, D' Souza S, Florescu MC. Hepatorenal Syndrome: Are We Missing Some Prognostic Factors Dig Dis Sci 2011 [In Press].